Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
How does the presence of both T790M and L858R EGFR mutations impact the prognosis and management of a patient with previously untreated locally advanced adenocarcinoma of the lung?
Related Questions
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
Would you consider the combination of amivantamab and lazertinib in a patient with NSCLC harboring an EGFR exon 19 deletion that transformed to small cell carcinoma on osimertinib, if resistance profiling still detects the EGFR mutation?
Is there any data supporting the use of osimertinib in patients with L858R-mutated lung cancer who had a durable response to prior EGFR TKI therapy, and who progressed 1-2 years after discontinuation of other EGFR inhibitors?
What would be the recommended sequencing of adjuvant chemotherapy, osimertinib, and postoperative radiation for a patient with NSCLC who was upstaged to stage III following resection with negative margins?
At what age do you stop LDCT chest for lung cancer screening?
How do you approach Tarlatamab use in an elderly patient with relapsed ES SCLC?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?
